Improvement of mechanical heart function by trimetazidine in db/db mice

Acta Pharmacologica Sinica

Volumn 31, Issue 5, 2010, Pages 560-569

  Li, Yuan Jing ^a   Wang, Pei Hua ^a   Chen, Chen ^a   Zou, Ming Hui ^b   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac protection; Cardiomyopathy; Diabetes; Diabetic cardiovascular complications; Heart; Mice; Mitochondria; Oxidative stress

Indexed keywords

ADENYLATE KINASE; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; TRIMETAZIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLE; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART CATHETER; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART OUTPUT; HEART PROTECTION; HEART RATE; HEART STROKE VOLUME; HEART VOLUME; IN VIVO STUDY; LIPID STORAGE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SYSTOLE; SYSTOLIC BLOOD PRESSURE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIOXIDANTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FATS; HEART; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; REACTIVE OXYGEN SPECIES; TRANS-ACTIVATORS; TRIGLYCERIDES; TRIMETAZIDINE;

EID: 77952067629     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.31     Document Type: Article

References (55)

1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-11.
2. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595-602.
3. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006;48:1688-97.
4. Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med 2006;41:851-61.
5. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003;108:754-9.
6. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784-9.
7. Wold LE, Ren J. Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinasedependent oxidative stress mechanism. Biochem Biophys Res Commun 2004;318:1066-71.
8. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemiainduced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002;51:1938-48.
9. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. H (2) O (2) regulates cardiac myocyte phenotype via concentrationdependent activation of distinct kinase pathways. J Mol Cell Cardiol 2003;35:615-21.
10. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006;55:798-805.
11. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 2002;51:174-81.
12. Matsushima S, Kinugawa S, Ide T, Matsusaka H, Inoue N, Ohta Y, et al. Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 2006;291: H2237-45.
13. Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004;53:1336-43.
14. Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail Rev 2002;7:149-59.
15. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 2002;105:1727-33. (Pubitemid 34298619)
16. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997;34:25-33.
17. Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 2005;1734:112-26.
18. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, et al. Reduced cardiac effciency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005;146:5341-9.
19. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac effciency in diabetic mice. Diabetes 2006;55:466-73.
20. Schrauwen P, Hesselink MK. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 2004;53:1412-7.
21. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/dbhGLUT4 mice. Am J Physiol Heart Circ Physiol 2002;283: H976-82.
22. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000;279: E1104-13.
23. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 2002;7:115-30.
24. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, et al. Short-and long-term benefcial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003;146: E18.
25. Thrainsdottir IS, von Bibra H, Malmberg K, Ryden L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 2004;44:101-8.
26. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8.
27. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003;2:16.
28. Gambert S, Vergely C, Filomenko R, Moreau D, Bettaieb A, Opie LH, et al. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem 2006;283:147-52.
29. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002;277:4098-103.
30. Kewalramani G, An D, Kim MS, Ghosh S, Qi D, Abrahani A, et al. AMPK control of myocardial fatty acid metabolism fuctuates with the intensity of insulin-defcient diabetes. J Mol Cell Cardiol 2007;42:333-42.
31. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121-30.
32. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994;37:279-88.
33. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a doubleblind, crossover study. Cardiovasc Drugs Ther 1990;4 Suppl 4:853-9.
34. Iskesen I, Saribulbul O, Cerrahoglu M, Var A, Nazli Y, Sirin H. Trimetazidine reduces oxidative stress in cardiac surgery. Circ J 2006;70:1169-73.
35. Ruiz-Meana M. Trimetazidine, oxidative stress, and cell injury during myocardial reperfusion. Rev Esp Cardiol 2005;58:895-7. Spanish.
36. Ovide-Bordeaux S, Bescond-Jacquet A, Grynberg A. Cardiac mitochondrial alterations induced by insulin deficiency and hyperinsulinaemia in rats: targeting membrane homeostasis with trimetazidine. Clin Exp Pharmacol Physiol 2005;32:1061-70.
37. Ikizler M, Erkasap N, Dernek S, Batmaz B, Kural T, Kaygisiz Z. Trimetazidine-induced enhancement of myocardial recovery during reperfusion: a comparative study in diabetic and non-diabetic rat hearts. Arch Med Res 2006;37:700-8.
38. Gunes Y, Guntekin U, Tuncer M, Sahin M. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 2009;24:277-82.
39. Van den Bergh A, Flameng W, Herijgers P. Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail 2006;8:777-83.
40. McGavock JM, Victor RG, Unger RH, Szczepaniak LS. Adiposity of the heart, revisited. Ann Intern Med 2006;144:517-24.
41. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004;18:1692-700.
42. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003;49:417-23.
43. Chatham JC, Gao ZP, Forder JR. Impact of 1 wk of diabetes on the regulation of myocardial carbohydrate and fatty acid oxidation. Am J Physiol 1999;277(2 Pt 1): E342-51.
44. Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, et al. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 2005;289: E328-36.
45. McFadden JW, Corl BA. Activation of AMP-activated protein kinase (AMPK) inhibits fatty acid synthesis in bovine mammary epithelial cells. Biochem Biophys Res Commun 2009;390:388-93.
46. Tritto I, Wang P, Kuppusamy P, Giraldez R, Zweier JL, Ambrosio G. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol 2005;46:89-98.
47. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999;277(1 Pt 1): E1-10.
48. Saha AK, Ruderman NB. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem 2003;253:65-70.
49. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002;30:1064-70.
50. Clark H, Carling D, Saggerson D. Covalent activation of heart AMP-activated protein kinase in response to physiological concentrations of long-chain fatty acids. Eur J Biochem 2004;271:2215-24.
51. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 2004;95:568-78.
52. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 2003;100:1226-31.
53. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulinresistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 2007;115:909-17.
54. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 2007;100:1208-17.
55. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006;116:615-22.